Novartis – Solving the "Undruggable" and the "Untreatable"

The evolution of a pharmaceutical pipeline is a story of strategic precision. Today, I’m highlighting 4 molecules from Novartis that demonstrate how the industry is moving toward more complex modalities to solve long-standing clinical challenges:

🔬 ONCOLOGY & HEMATOLOGY:

Luxdegalutamide (ARV-766)
The Challenge: Resistance in metastatic castration-resistant prostate cancer (mCRPC), particularly the L702H mutation.
The Solution: A second-generation AR PROTAC (Proteolysis Targeting Chimera). Instead of just blocking the Androgen Receptor, it tags it for total cellular degradation. Its ability to overcome specific resistance mutations makes it a potential game-changer for advanced patients.

Pelabresib (DAK539)
The Challenge: Myelofibrosis (MF) treatment often lacks deep disease modification beyond symptom control.
The Solution: An oral BET Inhibitor (acquired via MorphoSys). By targeting the epigenetic "readers" (bromodomains), it aims to reduce bone marrow fibrosis and inflammatory cytokines. The MANIFEST-2 data suggests that when combined with JAK inhibitors, it achieves deeper and more durable responses.

🧠 NEUROSCIENCE:

Votoplam (HTT227 / PTC518)
The Challenge: Reducing the toxic mutant Huntingtin (mHTT) protein in Huntington’s Disease without invasive procedures.
The Solution: An oral HTT mRNA Splicing Modulator. Developed in collaboration with PTC Therapeutics, Votoplam promotes the retention of a "pseudo-exon," leading to the degradation of the HTT transcript. It represents a shift from complex gene therapies to manageable oral small molecules for neurodegeneration.

🌍 GLOBAL HEALTH:

Ganaplacide / Lumefantrine (KLU156)
The Challenge: Rising parasite resistance to traditional Artemisinin-based therapies in Africa.
The Solution: A non-artemisinin combination. Ganaplacide is a novel imidazolopiperazine that disrupts the malaria parasite’s protein transport system. Recent Phase 3 results (Nov 2025) showed a 97.4% cure rate, offering a vital new weapon in the global fight against resistant malaria.

We are seeing a clear trend: Novartis is doubling down on "New Modalities." Whether it's degrading proteins (PROTACs), modulating RNA splicing, or epigenetic regulation, the focus is on targets that were once considered out of reach for small molecules.

Which of these modalities—Targeted Protein Degradation or RNA Splicing—do you believe will have the fastest adoption in clinical practice?

Comments

Curated Compendium of Drug Discovery

Drug discovery is a multidisciplinary process that integrates biology, chemistry, pharmacology , and cutting-edge technologies to identify and develop new therapeutic agents. From target identification to lead optimization and clinical evaluation, each stage requires precision, innovation, and collaboration. A curated list of drug discovery resources provides researchers, students, and professionals with a structured pathway to explore advancements, tools, and strategies that shape modern therapeutics. This compilation serves as a gateway to understanding the evolution of drug discovery, recent breakthroughs, and future directions, fostering knowledge-sharing and accelerating translational research. Databases and Chemical Libraries General Compound Libraries DrugBank - Comprehensive data on approved and investigational drugs. ZINC - Free compounds for screening. ChemSpider - Chemical structures and data. DrugSpaceX - Chemical and biological spaces. Mcule ...

Understanding NMR Spectroscopy and Chemical Shift Ranges for Functional Groups

Nuclear Magnetic Resonance ( NMR ) spectroscopy is one of the most powerful analytical tools in pharmaceutical chemistry. It helps chemists determine the structure, purity, and chemical environment of molecules by analyzing the behavior of nuclei (commonly ¹H or ¹³C ) when exposed to a strong magnetic field. In proton NMR ( ¹H-NMR ), the chemical shift (δ, in ppm) provides information about the type of hydrogen atoms present in a compound and their surrounding electronic environment. Depending on nearby atoms and functional groups, signals appear in specific regions of the spectrum — often referred to as upfield (shielded, lower δ values) or downfield (deshielded, higher δ values). The image above summarizes the characteristic δ ranges for different functional groups in ¹H-NMR. Let us break it down systematically: 1. Downfield Region (δ 12 – 6 ppm) Hydrogens in this region are strongly deshielded due to electronegative atoms or π-bond systems. Carboxylic Acids (–COOH) : δ 1...

Pushing the boundaries of computational drug discovery at Isomorphic Labs

The Isomorphic Labs Drug Design Engine (IsoDDE) has unlocked a new frontier in in-silico drug design, representing a significant evolution beyond AlphaFold 3. What IsoDDE delivers: 🔹 Massive accuracy leap on unconstrained structure prediction The engine more than doubles AlphaFold 3's accuracy on extremely challenging protein-ligand prediction tasks — including systems far outside the training distribution. 🔹 Best-in-class binding affinity prediction IsoDDE predicts how strongly small molecules bind to targets with accuracy that exceeds gold-standard physics-based methods, at a fraction of the computational cost and time. 🔹 Blind identification of novel binding pockets Even without existing structural data, the engine reveals previously unseen binding sites — just from an amino acid sequence — enabling drug designers to explore entirely new chemical action spaces. 🔹 Expanded support for complex biologics Beyond small molecules, the engine boosts prediction fidelity for...

NEOPHARMA NUTSHELL COMMUNITY

Search This Blog